A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
Gupta, K., Singh, S., and van Hoek, M.L., Antibiotics (Basel) , 2015, vol
Potential Side Effects (Rare and Mild): Injection site irritation or redness Mild digestive upset Temporary changes in hormone levels Slight water retention Our experienced team monitors your progress closely and adjusts your protocol to ensure safety and effectiveness throughout your treatment
The cost of lipotropic injections is not fixed